ANTI‐ASTHMATIC PROPERTIES OF A NEW PERORAL DRUG (HC 20–511.)
- 1 February 1977
- Vol. 32 (1), 27-34
- https://doi.org/10.1111/j.1398-9995.1977.tb02701.x
Abstract
A clinical trial was performed with a new substance (HC 20-511) [4-(1-methyl-4-piperidylidene)-4H] derived from the cycloheptothiophene group used in the management of asthma. Asthma patients (24) were treated at random with HC 20-511 or placebo or the antihistaminic substance clemastine (Tavegyl). A statistical evaluation of the results unequivocally demonstrated good protection with a single dose of 2.0 mg or 2 times 1.0 mg for 3 days against a challenging antigen, compared with the placebo or the antihistaminic agent. Tolerance was excellent.This publication has 2 references indexed in Scilit:
- Synthetical pharmaceutics. 9‐ and 10‐Oxo derivatives of 9,10‐dihydro‐4H‐benzo‐[4,5]‐cyclohepta[1,2b]thiophenesHelvetica Chimica Acta, 1976
- Treatment of Asthma with Disodium Cromoglycate (FPL 670, ‘Intal’)Respiration, 1969